Assessment of Safety and Satisfaction Toward COVID-19 Vaccines.

• Sponsor: Damanhour University (Other)
• Overall Status: Completed
• CT.gov ID: NCT05857176
• Collaborator: Alexandria University (Other)
• Enrollment: 508
• Location: 1
• Actual Duration (Months): 1.9
• Patients Per Site Per Month: 271.3

Study Details

Study Description

Brief Summary

This is a cross-sectional, web-based online survey done with the use of a Google Form-questionnaire to gather information from the general public regarding their knowledge, satisfaction, and tolerability about the COVID-19 vaccine.

Condition or Disease	Intervention/Treatment	Phase
COVID-19 Vaccine Adverse Reaction	Other: COVID-19 Vaccine questionnaire

Detailed Description

• A cross-sectional study was conducted. The subjects participating in the study are residents in Egypt.

• An online questionnaire, designed on Google Forms, was written in Arabic language and delivered to participants via social media (primarily Facebook, WhatsApp and Linkedin).

• The questionnaire comprised two categories of inquiries. The first is demographic data of the subject. The second is questions about COVID-19 vaccine-related data.

such as whether they had taken the vaccine or not, the type of vaccine administered, side effects encountered from the vaccine , if they got enough information regarding the vaccine and where did they obtain such information from and if they were reluctant to taking the vaccine and the reasons for their hesitancy. All participants were permitted to terminate the survey at any time of the study.

Study Design

• Study Type: Observational
• Actual Enrollment: 508 participants
• Observational Model: Other
• Time Perspective: Cross-Sectional
• Official Title: Assessment of Safety and Satisfaction Toward COVID-19 Vaccines: A Cross-sectional Study.
• Actual Study Start Date: Dec 15, 2021
• Actual Primary Completion Date: Feb 1, 2022
• Actual Study Completion Date: Feb 10, 2022

Outcome Measures

Primary Outcome Measures

1. headache incidence [3 month]

   Pecentage

2. fever incidence [3 month]

   Pecentage

3. fatigue incidence [3 month]

   Pecentage

4. pain at site of injection incidence [3 month]

   Pecentage

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• all adults (age ≥ 18 years) complete the questionnaire were considered eligible to participate in the survey.

Exclusion Criteria:

• Incomplete questionnaires were excluded from the final analysis.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Rehab Hussein Werida	Damanhūr	Elbehairah	Egypt	31527

Sponsors and Collaborators

• Damanhour University
• Alexandria University

Investigators

• Principal Investigator: Rehab H Werida, Ass. Prof., Damanhour University

Study Documents (Full-Text)

None provided.

More Information

Publications

• Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021 Feb;27(2):225-228. doi: 10.1038/s41591-020-1124-9. Epub 2020 Oct 20. Erratum In: Nat Med. 2021 Jan 11;:
• Malik A, Malik J, Ishaq U. Acceptance of COVID-19 vaccine in Pakistan among health care workers. PLoS One. 2021 Sep 15;16(9):e0257237. doi: 10.1371/journal.pone.0257237. eCollection 2021.

• Responsible Party: Rehab Werida, Principal Investigator, Damanhour University
• ClinicalTrials.gov Identifier: NCT05857176
• Other Study ID Numbers: COVID-19 vaccines Perception
• First Posted: May 12, 2023
• Last Update Posted: May 12, 2023
• Last Verified: May 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: COVID-19

Study Results

No Results Posted as of May 12, 2023